Rutgers startup Zena Therapeutics strives to create narcotic medications that will minimize or even eliminate overdoses from prescription drugs. Co-founded by Eileen Carry, PhD, and Ariane Vasilatis, PhD, the company is based on an innovation developed at Rutgers, The State University of New Jersey: a novel compound that does not increase the risk of overdose if taken with other central nervous system depressing substances such as opioids and alcohol.
Menu
Menu
